ATE398456T1 - Verwendung von negativ-geladenen phospholipiden zur herstellung eines medikaments zur behandlung und/oder vorbeugung von makuladegeneration - Google Patents

Verwendung von negativ-geladenen phospholipiden zur herstellung eines medikaments zur behandlung und/oder vorbeugung von makuladegeneration

Info

Publication number
ATE398456T1
ATE398456T1 AT02754804T AT02754804T ATE398456T1 AT E398456 T1 ATE398456 T1 AT E398456T1 AT 02754804 T AT02754804 T AT 02754804T AT 02754804 T AT02754804 T AT 02754804T AT E398456 T1 ATE398456 T1 AT E398456T1
Authority
AT
Austria
Prior art keywords
negatively charged
macular degeneration
phospholipides
medication
prevention
Prior art date
Application number
AT02754804T
Other languages
English (en)
Inventor
Christoph Richter
Paolo Gazzotti
Hamdy Shaban
Original Assignee
Lynkeus Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynkeus Biotech Gmbh filed Critical Lynkeus Biotech Gmbh
Application granted granted Critical
Publication of ATE398456T1 publication Critical patent/ATE398456T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02754804T 2001-08-22 2002-07-01 Verwendung von negativ-geladenen phospholipiden zur herstellung eines medikaments zur behandlung und/oder vorbeugung von makuladegeneration ATE398456T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10141018A DE10141018A1 (de) 2001-08-22 2001-08-22 Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges

Publications (1)

Publication Number Publication Date
ATE398456T1 true ATE398456T1 (de) 2008-07-15

Family

ID=7696167

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754804T ATE398456T1 (de) 2001-08-22 2002-07-01 Verwendung von negativ-geladenen phospholipiden zur herstellung eines medikaments zur behandlung und/oder vorbeugung von makuladegeneration

Country Status (7)

Country Link
US (1) US20030050283A1 (de)
EP (1) EP1418922B1 (de)
JP (1) JP2005501109A (de)
AT (1) ATE398456T1 (de)
CA (1) CA2458132A1 (de)
DE (2) DE10141018A1 (de)
WO (1) WO2003018028A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
WO2006034556A1 (en) * 2004-09-29 2006-04-06 Michael Ary Bos Caratenoid composition and method for preparation thereof
US20060252107A1 (en) * 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2007029008A2 (en) * 2005-09-08 2007-03-15 Dsm Ip Assets B.V. Method of treatment or prevention of age-related macular degeneration
CA2622475A1 (en) * 2005-09-26 2007-04-05 Vasogen Ireland Limited Treatment of inflammation and vascular abnormalities of the eye
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007096744A1 (en) * 2006-02-21 2007-08-30 Pfizer Products Inc. Methods for the treatment of macular degeneration and related eye conditions
BRPI0810063A2 (pt) * 2007-04-20 2014-10-14 Acucela Inc Composto, composição farmacêutica, e, métodos para modular fluxo de cromóforo em um ciclo retinóide, para tratar uma doença ou distúrbio oftálmico em um indivíduo, para inibir adaptação ao escuro em uma célula fotorreceptora de bastão da retina, para inibir regeneração de rodopsina em uma célula fotoreceptora de bastão da retina, para reduzir isquemia em um olho de um indivíduo, para inibir neovascularização na retina de um olho de um indivíduo, e para inibir degeneração de uma célula da retina em uma retina
CN103664637B (zh) 2007-06-29 2016-02-03 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
MX354184B (es) 2007-10-05 2018-02-16 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
US20090312438A1 (en) * 2008-06-13 2009-12-17 Bernstein Paul S Compositions and Methods for Attenuating the Formation of A2E in the Retinal Pigment Epithelium
EP2804605A4 (de) 2012-01-20 2015-07-08 Acucela Inc Substituierte heterocyclische verbindungen zur behandlung von krankheiten
AU2014248878A1 (en) 2013-03-12 2015-09-24 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
AP2017009684A0 (de) * 2014-08-11 2017-01-31

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
AU633078B2 (en) * 1989-04-04 1993-01-21 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
EP0459148B1 (de) * 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
ATE312353T1 (de) * 1991-09-09 2005-12-15 Canon Kk Quantitativer nachweis von verbindungen in coexistenz im system mit anderen verbindungen
AU719671B2 (en) * 1995-06-07 2000-05-18 Howard Foundation, The Pharmaceutically active carotenoids
US6075058A (en) * 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids

Also Published As

Publication number Publication date
EP1418922A1 (de) 2004-05-19
CA2458132A1 (en) 2003-03-06
EP1418922B1 (de) 2008-06-18
JP2005501109A (ja) 2005-01-13
DE10141018A1 (de) 2003-03-13
US20030050283A1 (en) 2003-03-13
DE60227178D1 (de) 2008-07-31
WO2003018028A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
ATE398456T1 (de) Verwendung von negativ-geladenen phospholipiden zur herstellung eines medikaments zur behandlung und/oder vorbeugung von makuladegeneration
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
ATE537814T1 (de) Nanoliposom mit verestertem lecithin und herstellungsverfahren dafür und dieses enthaltende zusammensetzung zur prävention oder behandlung von hauterkrankungen
ATE230607T1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE497391T1 (de) Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE386504T1 (de) Vesikel-verkapselte kortikosteroide zur behandlung von krebs
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
ATE293976T1 (de) Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
BRPI0406477A (pt) Composição, agente de tratamento de óleo, e, métodos de produção de uma composição e de tratamento de óleo
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties